RG

REGENXBIO

- NASDAQ:RGNX
Last Updated 2024-04-12

LinkedIn Profile

Access REGENXBIO historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:rgnx 440337 Apr 14th, 2024 12:00AM REGENXBIO Inc. 30K 367.00 Open Apr 13th, 2024 11:37PM Apr 13th, 2024 11:37PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 13th, 2024 12:00AM REGENXBIO Inc. 30K 367.00 Open Apr 12th, 2024 11:29PM Apr 13th, 2024 12:03PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 12th, 2024 12:00AM REGENXBIO Inc. 30K 367.00 Open Apr 11th, 2024 11:35PM Apr 12th, 2024 08:58AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 11th, 2024 12:00AM REGENXBIO Inc. 30K 367.00 Open Apr 11th, 2024 12:08AM Apr 11th, 2024 11:43AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 10th, 2024 12:00AM REGENXBIO Inc. 30K 367.00 Open Apr 9th, 2024 11:37PM Apr 10th, 2024 05:51PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 9th, 2024 12:00AM REGENXBIO Inc. 30K 368.00 Open Apr 8th, 2024 11:48PM Apr 9th, 2024 10:32AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 8th, 2024 12:00AM REGENXBIO Inc. 30K 368.00 Open Apr 8th, 2024 12:17AM Apr 8th, 2024 07:29PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 7th, 2024 12:00AM REGENXBIO Inc. 30K 368.00 Open Apr 6th, 2024 11:42PM Apr 6th, 2024 11:42PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 6th, 2024 12:00AM REGENXBIO Inc. 30K 369.00 Open Apr 5th, 2024 11:43PM Apr 5th, 2024 11:43PM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology
nasdaq:rgnx 440337 Apr 5th, 2024 12:00AM REGENXBIO Inc. 30K 369.00 Open Apr 5th, 2024 12:18AM Apr 5th, 2024 12:18AM REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees. Open Biotechnology, Biopharmaceuticals, and Gene Therapy Open 9804 Medical Center Dr Rockville Maryland US 20850 REGENXBIO Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.